Table 1 Baseline characteristics of study population
From: A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease
Variables | Patients number (N = 34) |
|---|---|
Age (mean, years) | 47.29 ± 11.29 |
Gender (%) | |
Male | 12 (35.3%) |
Female | 22 (64.7%) |
Family history of ADPKD (%) | 28 (82.4%) |
Mother related | 11 (32.4%) |
Father related | 17 (50%) |
None | 6 (17.6%) |
Age at diagnosis (mean, years) | 35.97 ± 11.66 |
BMI (mean, kg/m2) | 27.10 ± 3.65 |
25–29.9 (%) | 17 (50%) |
≥ 30 (%) | 8 (23.5%) |
Smoking status (%) | |
Current smoker | 10 (29.4%) |
Past smoker | 6 (17.6%) |
Non-smoker | 18 (52.9%) |
History of hematuria (%) | 4 (11.8%) |
History of kidney stones (%) | 12 (35.3%) |
History of lumbar pain (%) | 28 (82.4%) |
History of UTI (%) | 14 (44.1%) |
HTN (%) | 26 (76.5%) |
Dyslipidemia (%) | 23 (67.6%) |
SBP (mean, mmHg) | 136.18 ± 15.42 |
DBP (mean, mmHg) | 83.09 ± 11.54 |
Serum creatinine (median, mg/dl) | 1.11 (0.88–2.61) |
eGFR (mean, ml/min/1.73m2) | 60.45 ± 34.71 |
CKD stage (%) | |
1 | 8 (23.5%) |
2 | 10 (29.4%) |
3 | 5 (14.7%) |
4 | 6 (17.6%) |
5 | 5 (14.7%) |
Serum urea (median, mg/dl) | 59 (36.42–80.75) |
Glucose level (mean, mg/dl) | 87.75 ± 15.90 |
Total cholesterol (mean, mg/dl) | 186.88 ± 37.32 |
Triglycerides (median, mg/dl) | 95.50 (70–145.25) |
Antihypertensive treatment (%) | 21 (61.8%) |
ACEI/ARB (%) | 18 (52.9%) |
Urine specific gravity (mean) | 1012 ± 6.39 |